11 June 2024
11 June 2024
All eleven members of an FDA advisory committee voted yes in favour of approving Lilly’s donanemab for the treatment of Alzheimer’s disease.
Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed.
The sNDA is supported by results from the global LAURA Phase III trial.
Eisai and Biogen consider expanded regimen options for their Alzheimer’s disease drug, as experts debate the reach of Eli Lilly’s donanemab.
Boehringer and Zealand have shared new data that builds on previously announced results with survodutide in MASH.
Marengo will receive an undisclosed upfront payment and milestone-based amounts for a total value of up to $1.2bn.
Works at the plant are planned to commence in the second half of 2024 and be fully operational by 2027.
The seed funding round headed by Pontifax and received support from a consortium of top-tier life science investors.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
